STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 23 - Issue 3, July-September 2021
ORIGINAL
EFFECTIVENESS OF NIVOLUMAB AS SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
ALCARAZ SÁNCHEZ JUAN JOSÉ, DEL RÍO VALENCIA JUAN CARLOS, MORA RODRÍGUEZ BEATRIZ, MUÑOZ CASTILLO ISABEL


Introduction: Immunotherapy has become a standard treatment for lung cancer; the objective of this study was to evaluate the effectiveness, safety of nivolumab in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) used as second-line treatment in real-world clinical practice.

Method: Retrospective observational study of every patients treated with nivolumab in our center from January 2016 to December 2018. Outcomes collected: sex, age, ECOG, PDL-1 levels, number of metastases, previous metastatic line therapies and adverse events (AE).

Results: A total of 40 patients were reviewed, 24 with squamous NSCLC and 16 with non-squamous NSCLC. The median age was 62 (38-82) years, 32 (80%) were men. 72.5% of patients had ECOG 1 and 7.5% ≥2. 17.5% of patients had central nervous system (CNS) metastases at the time of starting treatment. The median duration and number of cycles administered with nivolumab in second-line was 90 (12-1,113) days and 6 (1-77), respectively. OS was 8.67 (95% CI: 2.2 - not reached) months while in the squamous NSCLC patient group (No. = 24) was 6.23 (95% CI: 3.37-14.67) months (p = 0.5). In the non-squamous NSCLC patient group (No. = 16) the PFS was 2.07 (95% CI: 0.93 - not reached) months while in the squamous NSCLC patient group (No. = 24) was 3.70 (95% CI: 2.53-10.76) months (p = 1). 83% of patients presented some AE to nivolumab, with a median of 2 (0-8) AE/patient.

Conclusion: Nivolumab represents an effective and feasible alternative in terms of PFS. It is a well-tolerated treatment option.

IMMUNOTHERAPY – NIVOLUMAB – NON-SMALL-CELL LUNG CANCER



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25